Will AI transform the way we edit genes?

Artificial intelligence (AI) is transforming genome editing, allowing scientists to design enzymes that go beyond the limits of natural biology.

In this webinar, our experts showcase how AI-engineered base editors are achieving unprecedented precision and efficiency in therapeutic development.

See how the integration of AI-driven enzyme design with advanced editing platforms is reshaping the path from discovery to clinical application, offering new possibilities for safer, more adaptable and scalable genetic therapies.

• Understand how AI-driven protein design expands the enzyme landscape
• Discover the advantages of modular base editing with the Pin-point™ base editing platform
• Explore how AI-enhanced enzymes elevate editing performance
• Learn how streamlined access accelerates therapeutic innovation

Speakers:

Pablo Perez Duran, PhD
Manager, R&D, Base Editing, Revvity

Peter Cameron, PhD
Senior Vice President, Profluent Bio

The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.